{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:06:46Z","timestamp":1794614806323,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82260717"],"award-info":[{"award-number":["No. 82260717"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82160708"],"award-info":[{"award-number":["No. 82160708"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02259-0","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T02:33:04Z","timestamp":1740623584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hsa_circ_0125356 promotes gemcitabine resistance by modulating WNT canonical and non-canonical pathways via miR-582-5p\/FGF9 axis in non-small cell lung cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Xinyue","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanglan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2259_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941\u201353.","journal-title":"Int J Cancer"},{"key":"2259_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-319-23730-5_9","volume":"889","author":"VV Del","year":"2015","unstructured":"Del VV, Denti MA. microRNA and Lung Cancer. Adv Exp Med Biol. 2015;889:153\u201377.","journal-title":"Adv Exp Med Biol"},{"key":"2259_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.canlet.2019.10.044","volume":"469","author":"C Seidl","year":"2020","unstructured":"Seidl C, Panzitt K, Bertsch A, Brcic L, Schein S, Mack M, Leithner K, Prinz F, Olschewski H, Kornmueller K, Hrzenjak A. MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2. Cancer Lett. 2020;469:266\u201376.","journal-title":"Cancer Lett"},{"key":"2259_CR4","doi-asserted-by":"publisher","first-page":"1393392085","DOI":"10.1177\/1010428317697579","volume":"39","author":"L Zhong","year":"2017","unstructured":"Zhong L, Sun S, Shi J, Cao F, Han X, Chen Z. MicroRNA-125a-5p plays a role as a tumor suppressor in lung carcinoma cells by directly targeting STAT3. Tumour Biol. 2017;39:1393392085.","journal-title":"Tumour Biol"},{"key":"2259_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.omtn.2019.09.007","volume":"18","author":"RK Dutta","year":"2019","unstructured":"Dutta RK, Chinnapaiyan S, Unwalla H. Aberrant MicroRNAomics in Pulmonary Complications: Implications in Lung Health and Diseases. Mol Ther Nucleic Acids. 2019;18:413\u201331.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2259_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2174\/1389202916666150707161554","volume":"16","author":"L Chen","year":"2015","unstructured":"Chen L, Huang C, Wang X, Shan G. Circular RNAs in Eukaryotic Cells. Curr Genomics. 2015;16:312\u20138.","journal-title":"Curr Genomics"},{"issue":"3","key":"2259_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/genes13030466","volume":"13","author":"B Pandit","year":"2022","unstructured":"Pandit B, Royzen M. Recent Development of Prodrugs of Gemcitabine. Genes (Basel). 2022;13(3):466.","journal-title":"Genes (Basel)."},{"key":"2259_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00262-020-02738-x","volume":"70","author":"H Jiang","year":"2021","unstructured":"Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, et al. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. Cancer Immunol Immunother. 2021;70:857\u201368.","journal-title":"Cancer Immunol Immunother"},{"key":"2259_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lungcan.2008.04.006","volume":"63","author":"I Boukovinas","year":"2009","unstructured":"Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, Polyzos A, Geroyianni A, Agelidou A, Agelaki S, et al. Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study. Lung Cancer. 2009;63:77\u201382.","journal-title":"Lung Cancer"},{"key":"2259_CR10","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/S0140-6736(00)04644-4","volume":"357","author":"V Georgoulias","year":"2001","unstructured":"Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357:1478\u201384.","journal-title":"Lancet"},{"issue":"Suppl 5","key":"2259_CR11","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(Suppl 5):v7\u201312.","journal-title":"Ann Oncol"},{"key":"2259_CR12","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2\u2019,2\u2019-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110\u20137.","journal-title":"Cancer Res"},{"key":"2259_CR13","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.3748\/wjg.v20.i26.8482","volume":"20","author":"S Nordh","year":"2014","unstructured":"Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol. 2014;20:8482\u201390.","journal-title":"World J Gastroenterol"},{"key":"2259_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2017.07.002","volume":"404","author":"G Huang","year":"2017","unstructured":"Huang G, Li S, Yang N, Zou Y, Zheng D, Xiao T. Recent progress in circular RNAs in human cancers. Cancer Lett. 2017;404:8\u201318.","journal-title":"Cancer Lett"},{"key":"2259_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.molcel.2013.08.017","volume":"51","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, Zhu S, Yang L, Chen LL. Circular intronic long noncoding RNAs. Mol Cell. 2013;51:792\u2013806.","journal-title":"Mol Cell"},{"key":"2259_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nsmb.2959","volume":"22","author":"Z Li","year":"2015","unstructured":"Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22:256\u201364.","journal-title":"Nat Struct Mol Biol"},{"key":"2259_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1261\/rna.047126.114","volume":"20","author":"E Lasda","year":"2014","unstructured":"Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA. 2014;20:1829\u201342.","journal-title":"RNA"},{"key":"2259_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12943-019-1080-5","volume":"18","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhou Q, Qiu Q, Hou L, Wu M, Li J, Li X, Lu B, Cheng X, Liu P, et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9\/BRCA1\/DNAJB6\/KLF4\/AKT1 axis in ovarian cancer. Mol Cancer. 2019;18:144.","journal-title":"Mol Cancer"},{"key":"2259_CR19","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1111\/cas.14211","volume":"110","author":"Z Li","year":"2019","unstructured":"Li Z, Ruan Y, Zhang H, Shen Y, Li T, Xiao B. Tumor-suppressive circular RNAs: Mechanisms underlying their suppression of tumor occurrence and use as therapeutic targets. Cancer Sci. 2019;110:3630\u20138.","journal-title":"Cancer Sci"},{"key":"2259_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bbrc.2018.10.087","volume":"506","author":"H Yu","year":"2018","unstructured":"Yu H, Chen Y, Jiang P. Circular RNA HIPK3 exerts oncogenic properties through suppression of miR-124 in lung cancer. Biochem Biophys Res Commun. 2018;506:455\u201362.","journal-title":"Biochem Biophys Res Commun"},{"key":"2259_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbrc.2018.11.079","volume":"508","author":"Y Yao","year":"2019","unstructured":"Yao Y, Hua Q, Zhou Y. CircRNA has_circ_0006427 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p\/DKK1 axis and inactivating Wnt\/\u03b2-catenin signaling pathway. Biochem Biophys Res Commun. 2019;508:37\u201345.","journal-title":"Biochem Biophys Res Commun"},{"key":"2259_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bbrc.2019.08.093","volume":"519","author":"L Yan","year":"2019","unstructured":"Yan L, Liu G, Cao H, Zhang H, Shao F. Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation. Biochem Biophys Res Commun. 2019;519:172\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"2259_CR23","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.2147\/CMAR.S263083","volume":"12","author":"W Huang","year":"2020","unstructured":"Huang W, Lu Y, Wang F, Huang X, Yu Z. Circular RNA circRNA_103809 Accelerates Bladder Cancer Progression and Enhances Chemo-Resistance by Activation of miR-516a-5p\/FBXL18 Axis. Cancer Manag Res. 2020;12:7561\u20138.","journal-title":"Cancer Manag Res"},{"key":"2259_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2018.12.021","volume":"176","author":"JN Vo","year":"2019","unstructured":"Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, et al. The Landscape of Circular RNA in Cancer. Cell. 2019;176:869\u201381.","journal-title":"Cell"},{"key":"2259_CR25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00726-022-03143-7","volume":"54","author":"A Li","year":"2022","unstructured":"Li A, Li XM, Song CG, Xiao X, Yao WM, Tian HS. Fibroblast growth factor 9 attenuates sepsis-induced fulminant hepatitis in mice. Amino Acids. 2022;54:1069\u201381.","journal-title":"Amino Acids"},{"key":"2259_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/cells13040307","volume":"13","author":"CC Chang","year":"2024","unstructured":"Chang CC, Takada YK, Cheng CW, Maekawa Y, Mori S, Takada Y. FGF9, a potent mitogen, is a new ligand for integrin \u03b1v\u03b23, and the FGF9 mutant defective in integrin binding acts as an antagonist. Cells. 2024;13:307\u201320.","journal-title":"Cells."},{"key":"2259_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12933","volume":"54","author":"F Yang","year":"2021","unstructured":"Yang F, Whelan EC, Guan X, Deng B, Wang S, Sun J, Avarbock MR, Wu X, Brinster RL. FGF9 promotes mouse spermatogonial stem cell proliferation mediated by p38 MAPK signalling. Cell Prolif. 2021;54: e12933.","journal-title":"Cell Prolif"},{"issue":"11","key":"2259_CR28","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/biom12111639","volume":"12","author":"Y Sun","year":"2022","unstructured":"Sun Y, Ying X, Li R, Weng M, Shi J, Chen Z. FGF9 Promotes Expression of HAS2 in Palatal Elevation via the Wnt\/\u03b2-Catenin\/TCF7L2 Pathway. Biomolecules. 2022;12(11):1639.","journal-title":"Biomolecules."},{"key":"2259_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1021\/jm801144h","volume":"52","author":"WJ Moore","year":"2009","unstructured":"Moore WJ, Kern JC, Bhat R, Commons TJ, Fukayama S, Goljer I, Krishnamurthy G, Magolda RL, Nogle L, Pitts K, et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J Med Chem. 2009;52:105\u201316.","journal-title":"J Med Chem"},{"key":"2259_CR30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nature08356","volume":"461","author":"SM Huang","year":"2009","unstructured":"Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614\u201320.","journal-title":"Nature"},{"key":"2259_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/jcb.27428","volume":"120","author":"J Sui","year":"2019","unstructured":"Sui J, Yang S, Liu T, Wu W, Xu S, Yin L, Pu Y, Zhang X, Zhang Y, Shen B, Liang G. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature. J Cell Biochem. 2019;120:705\u201314.","journal-title":"J Cell Biochem"},{"key":"2259_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535\u201354.","journal-title":"Lancet"},{"key":"2259_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17:637\u201358.","journal-title":"Nat Rev Cancer"},{"key":"2259_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fphar.2020.00343","volume":"11","author":"J Zhou","year":"2020","unstructured":"Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, Yu L. The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Front Pharmacol. 2020;11:343.","journal-title":"Front Pharmacol"},{"key":"2259_CR35","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/15384047.2019.1617563","volume":"20","author":"YZ Wang","year":"2019","unstructured":"Wang YZ, An Y, Li BQ, Lu J, Guo JC. Research progress on circularRNAs in pancreatic cancer: emerging but promising. Cancer Biol Ther. 2019;20:1163\u201371.","journal-title":"Cancer Biol Ther"},{"key":"2259_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/cbin.11473","volume":"45","author":"H Zhu","year":"2021","unstructured":"Zhu H, Du F, Cao C. Restoration of circPSMC3 sensitizes gefitinib-resistant esophageal squamous cell carcinoma cells to gefitinib by regulating miR-10a-5p\/PTEN axis. Cell Biol Int. 2021;45:107\u201316.","journal-title":"Cell Biol Int"},{"key":"2259_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.bbrc.2018.11.157","volume":"508","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zheng X, Xu B, Chen L, Wang Q, Deng H, Jiang J. Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183\/PDPK1 signaling pathway. Biochem Biophys Res Commun. 2019;508:527\u201335.","journal-title":"Biochem Biophys Res Commun"},{"key":"2259_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cca.2021.09.013","volume":"523","author":"M Zhang","year":"2021","unstructured":"Zhang M, Bai X, Zeng X, Liu J, Liu F, Zhang Z. circRNA-miRNA-mRNA in breast cancer. Clin Chim Acta. 2021;523:120\u201330.","journal-title":"Clin Chim Acta"},{"key":"2259_CR39","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.7150\/ijbs.84994","volume":"19","author":"W Chen","year":"2023","unstructured":"Chen W, Xu J, Wu Y, Liang B, Yan M, Sun C, Wang D, Hu X, Liu L, Hu W, et al. The potential role and mechanism of circRNA\/miRNA axis in cholesterol synthesis. Int J Biol Sci. 2023;19:2879\u201396.","journal-title":"Int J Biol Sci"},{"key":"2259_CR40","doi-asserted-by":"publisher","first-page":"13659","DOI":"10.1038\/s41598-020-70484-2","volume":"10","author":"S Bai","year":"2020","unstructured":"Bai S, Wu Y, Yan Y, Shao S, Zhang J, Liu J, Hui B, Liu R, Ma H, Zhang X, Ren J. Construct a circRNA\/miRNA\/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma. Sci Rep. 2020;10:13659.","journal-title":"Sci Rep"},{"key":"2259_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.omtn.2019.01.004","volume":"16","author":"S Huang","year":"2019","unstructured":"Huang S, Zou C, Tang Y, Wa Q, Peng X, Chen X, Yang C, Ren D, Huang Y, Liao Z, et al. miR-582-3p and miR-582-5p Suppress Prostate Cancer Metastasis to Bone by Repressing TGF-\u03b2 Signaling. Mol Ther Nucleic Acids. 2019;16:91\u2013104.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2259_CR42","doi-asserted-by":"publisher","first-page":"10126","DOI":"10.1080\/21655979.2021.2000741","volume":"12","author":"X Zeng","year":"2021","unstructured":"Zeng X, Ma X, Guo H, Wei L, Zhang Y, Sun C, Han N, Sun S, Zhang N. MicroRNA-582-5p promotes triple-negative breast cancer invasion and metastasis by antagonizing CMTM8. Bioengineered. 2021;12:10126\u201335.","journal-title":"Bioengineered"},{"key":"2259_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12957-016-0984-4","volume":"14","author":"Z Shu","year":"2016","unstructured":"Shu Z, Chen L, Ding D. miR-582-5P induces colorectal cancer cell proliferation by targeting adenomatous polyposis coli. World J Surg Oncol. 2016;14:239.","journal-title":"World J Surg Oncol"},{"key":"2259_CR44","doi-asserted-by":"publisher","first-page":"14981","DOI":"10.1038\/s41598-020-70913-2","volume":"10","author":"Y Hu","year":"2020","unstructured":"Hu Y, Su Y, Lei X, Zhao H, Wang L, Xu T, Guo J, Yang W, Zhang X. LINC00641\/miR-582-5p mediate oxaliplatin resistance by activating autophagy in gastric adenocarcinoma. Sci Rep. 2020;10:14981.","journal-title":"Sci Rep"},{"key":"2259_CR45","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.18632\/aging.203905","volume":"14","author":"Z Xu","year":"2022","unstructured":"Xu Z, Cai Y, Liu W, Kang F, He Q, Hong Q, Zhang W, Li J, Yan Y, Peng J. Downregulated exosome-associated gene FGF9 as a novel diagnostic and prognostic target for ovarian cancer and its underlying roles in immune regulation. Aging (Albany NY). 2022;14:1822\u201335.","journal-title":"Aging (Albany NY)"},{"key":"2259_CR46","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1080\/21691401.2019.1620250","volume":"47","author":"G Cui","year":"2019","unstructured":"Cui G, Shao M, Gu X, Guo H, Zhang S, Lu J, Ma H. The value of FGF9 as a novel biomarker in the diagnosis of prostate cancer. Artif Cells Nanomed Biotechnol. 2019;47:2241\u20135.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2259_CR47","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1158\/0008-5472.CAN-20-4048","volume":"81","author":"K Ishioka","year":"2021","unstructured":"Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, et al. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 2021;81:3916\u201329.","journal-title":"Cancer Res"},{"key":"2259_CR48","first-page":"1711","volume":"19","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang Y, Qin X, Wang Y, Fu J. FGF9 promotes cisplatin resistance in colorectal cancer via regulation of Wnt\/\u03b2-catenin signaling pathway. Exp Ther Med. 2020;19:1711\u20138.","journal-title":"Exp Ther Med"},{"key":"2259_CR49","doi-asserted-by":"publisher","first-page":"bio051680","DOI":"10.1242\/bio.051680","volume":"5","author":"L Li","year":"2020","unstructured":"Li L, Zhang C, Li Y, Zhang Y, Lei Y. DJ-1 promotes epithelial-to-mesenchymal transition via enhancing FGF9 expression in colorectal cancer. Biol Open. 2020;5:bio051680.","journal-title":"Biol Open."},{"key":"2259_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/hep.26315","volume":"58","author":"H Yang","year":"2013","unstructured":"Yang H, Fang F, Chang R, Yang L. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor \u03b2 receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 2013;58:205\u201317.","journal-title":"Hepatology"},{"key":"2259_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020;19:165.","journal-title":"Mol Cancer"},{"key":"2259_CR52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/mol.119.117978","volume":"97","author":"Z Zhong","year":"2020","unstructured":"Zhong Z, Virshup DM. Wnt Signaling and Drug Resistance in Cancer. Mol Pharmacol. 2020;97:72\u201389.","journal-title":"Mol Pharmacol"},{"key":"2259_CR53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2021.10.034","volume":"525","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Xu J, Luo H, Meng X, Chen M, Zhu D. Wnt signaling pathway in cancer immunotherapy. Cancer Lett. 2022;525:84\u201396.","journal-title":"Cancer Lett"},{"key":"2259_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/pros.23939","volume":"80","author":"X Chen","year":"2020","unstructured":"Chen X, Liu J, Cheng L, Li C, Zhang Z, Bai Y, Wang R, Han T, Huang C, Kong Y, et al. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer. Prostate. 2020;80:256\u201366.","journal-title":"Prostate"},{"key":"2259_CR55","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1038\/s41467-020-17770-9","volume":"11","author":"W Wang","year":"2020","unstructured":"Wang W, Li M, Ponnusamy S, Chi Y, Xue J, Fahmy B, Fan M, Miranda-Carboni GA, Narayanan R, Wu J, Wu ZH. ABL1-dependent OTULIN phosphorylation promotes genotoxic Wnt\/\u03b2-catenin activation to enhance drug resistance in breast cancers. Nat Commun. 2020;11:3965.","journal-title":"Nat Commun"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02259-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02259-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02259-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T03:11:48Z","timestamp":1740625908000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02259-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2259"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02259-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors agreed to the publication of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}